The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial

Post time Half hour(s) ago

journal：The Lancet Gastroenterology & Hepatology

Authors：Prof Mazen Noureddin, MD; Prof Winston Dunn, MD; Rashmee Patil, MD; Dimple Desai, MD; Rohit Puskoor, MD; Jaehee Shin, MS; Dennis To, PhD; Adam C Bell, PhD; Daniel R Lee, MS; Yen-Huei Lin, PhD; Seulki Lee, PhD

Published date：2026-8-21

DOI：10.1016/S2468-1253(26)00130-5

PDF link：https://www.sciencedirect.com/science/article/pii/S2468125326001305/pdf

Article link: https://doi.org/10.1016/S2468-1253(26)00130-5

Article Source：Elsevier BV。

Remark：

Post time 24 min. ago

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[Elsevier] The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial Copy

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial